Hiroaki Mitsuya

USPTO Granted Patents = 25 (Patent Applications = 7)

CIPO Patents = 1

EPO Patents = 3 (Patent Applications = 8)

Average Co-Inventor Count = 3.7

ph-index = 6

Forward Citations = 93(Granted Patents)

Location History:

Chevy Chase, MD (US) (2008 - 2018)
Kumamoto, JP (2001 - 2023)

Company Filing History:

15 out of 2,656

Purdue Research Foundation

National Institutes of Health, a Component of the US Dept. of Health & Human Services

patents

5. 3 out of 2,340

University of Illinois

patents

6. 1 out of 22

Ono Pharmaceuticals Co., Ltd.

where one patent can have more than one assignee

Years Active: 2001-2025

Loading Chart...

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12454537 - HIV-1 protease inhibitors and uses thereof (2025-10-28),

2. 11795159 - Compounds for the treatment of SARS (2023-10-24),

3. 11390630 - Tricyclic P2-ligand containing potent HIV-protease inhibitors against HIV/AIDS (2022-07-19),

4. 11230550 - Macrocyclic HIV-1 protease inhibitors and uses thereof (2022-01-25),

5. 11028096 - Tricyclic P2-ligand containing potent HIV-protease inhibitors against HIV/AIDS (2021-06-08),

6. 10472372 - HIV-1 protease inhibitors and uses thereof (2019-11-12),

7. 9889115 - Fitness assay and associated methods (2018-02-13),

8. 9808527 - Methods and compositions for treating HIV infections (2017-11-07),

9. 9670225 - HIV-1 protease inhibitors and uses thereof (2017-06-06),

10. 9499558 - Compounds and methods for treating HIV (2016-11-22),

11. 9487541 - Fused tricyclic ether carbamates and their use (2016-11-08),

12. 9346820 - HIV-1 protease inhibitors having gem-di-fluoro bicyclic P2-ligands (2016-05-24),

13. 9309213 - C-3 substituted bicyclooctane based HIV protease inhibitors (2016-04-12),

14. 9062057 - CCR5 antagonists for treating HIV (2015-06-23),

15. 9024038 - Compunds and methods for treating HIV (2015-05-05),

Title: **Hiroaki Mitsuya: A Notable Contributor to Pharmaceutical Innovations**

Introduction

Hiroaki Mitsuya, based in Kumamoto, Japan, is a distinguished inventor recognized for his significant contributions to the field of pharmaceuticals. With a remarkable portfolio of 24 patents, Mitsuya's work primarily focuses on the development of treatments for viral infections, including SARS and HIV/AIDS.

Latest Patents

Mitsuya's latest innovations include compounds for the treatment of SARS, specifically bis-amide inhibitors targeting SARS-CoV-2 (COVID). His patents also encompass pharmaceutical compositions comprising these inhibitors and methods for treating severe acute respiratory syndrome. Additionally, he has developed tricyclic P2-ligands that contain potent HIV-protease inhibitors, offering various embodiments that relate to specific chemical formulas. These innovations are crucial for both therapeutic composition and effective treatment methods for HIV infection.

Career Highlights

Throughout his career, Hiroaki Mitsuya has made significant strides while working with prestigious organizations such as the Purdue Research Foundation and Yamasa Corporation. His expertise and dedication have placed him at the forefront of pharmaceutical research and development.

Collaborations

Mitsuya has had fruitful collaborations with prominent colleagues such as Arun K. Ghosh and Hiroshi Ohrui. These partnerships have fostered a rich environment for innovation, leading to the advancement of promising treatments through shared knowledge and expertise.

Conclusion

Hiroaki Mitsuya continues to be a pivotal figure in the realm of pharmaceutical innovations. His extensive work on patents addressing pressing health challenges like SARS and HIV/AIDS underscores his commitment to improving global health outcomes through scientific advancements.

This text is generated by artificial intelligence and may not be accurate.